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Abstract Cathepsin G (CatG) is an endopeptidase that is
associated with the early immune response. The synthetic
compound cathepsin G inhibitor I (CGI-I) was tested for
its ability to inhibit the activity of CatG via a new
surface plasmon resonance imaging assay. CGI-I was
i m m o b i l i z e do nt h eg o l ds u r f a c eo fa nS P Rs e n s o rt h a t
was first modified with 1-octadecanethiol. A concentra-
tion of CGI-I equal to 4.0 μg·mL-1 and a pH of 8.0 were
found to give the best results. The dynamic response of
the sensor ranges from 0.25 to 1.5 ng·mL-1, and the
detection limit is 0.12 ng·mL-1. The sensor was applied
to detect CatG in human saliva and white blood cells.
Keywords Biosensor.Cathepsin G.CathepsinGinhibitorI.
Surface plasmon resonance imaging
Introduction
CathepsinG(EC3.4.21.20)isoneoftheserineendopeptidases.
It is stored in the azurophilic granules of neutrophilic
polymorphonuclear leukocytes, but is also present in
monocytes and mast cells [1].
The physiological role of cathepsin G (CatG) in the
living organism is mainly associated with early immune
response, but its biological activity is not limited to this.
CatG is involved in several physiological processes such
as tissue degradation, platelet activation, monocyte and
neutrophil chemotaxis, proteolysis of blood coagulation
factors, and generation of angiotensin II. It also displays
a broad spectrum of antiviral, antibacterial, and antifungal
activities. The potent antibacterial activity of CatG is
independent of its proteolytic activity. The antibacterial action
of CatG is thought to contribute significantly to the non-
oxidative antibacterial capacity of neutrophils [2–5].
Together with similarly localized human neutrophil
elastase and proteinase 3, CatG represents a major class of
enzymes utilized in the phagocythic pathways to degrade
foreign organisms and dead tissues during inflammatory
reactions. Neutrophils play a key role in host defense by
migrating to sites of infection, where they phagocytose
invading microorganisms. After a neutrophil encloses a
microbe, the resulting phagosome fuses with granules
containing microbicidal and digestive enzymes to form a
phagolysosome. The azurophilic granules of neutrophils are
rich in serine proteases, including CatG and neutrophil
elastase, which play critical roles in killing bacteria.
Neutrophils are also known to invade many tumor tissues
and influence tumor development, whereas CatG in
neutrophils has a role in the dissemination of tumor
aggregates from orimary tumor sites later to be secreted
out by infiltrated neutrophils [5–7].
Activity of CatG, as well as other serine endopeptidases,
is controlled by one or more members of the serine
proteinase inhibitor (serpin) protein superfamily. However,
an imbalance between proteases and serpins is implicated in
E. Gorodkiewicz (*): K. Wojtulewski
Department of Electrochemistry, Institute of Chemistry,
University of Bialystok,
Al.J.Pilsudskiego11/4,
PL-15-443 Bialystok, Poland
e-mail: ewka@uwb.edu.pl
E. Regulska
Department of General and Inorganic Chemistry,
Institute of Chemistry, University of Bialystok,
Hurtowa 1,
PL-15-399 Bialystok, Poland
Microchim Acta (2011) 173:407–413
DOI 10.1007/s00604-011-0569-4tissue damage during inflammation [6]. In ischaemic
diseases the impaired balance between CatG and its
physiological inhibitors leads to tissue destruction and
platelet aggregation. Inhibitors of CatG are thus suitable for
the treatment of inflammatory diseases and procoagulant
conditions [8]. Serpins can fail quantitatively or qualitatively
in down-regulation due to genetic or acquired deficiencies.
This results in the disturbed digestion of extracellular
proteins that could contribute to the development of
connective tissue diseases, such as emphysema, rheumatoid
arthritis and perionditis [6].
Information concerning the determination of CatG is very
scanty. Activities of CatG were determined using highly
sensitive Abz-peptidyl-EDDnp fluorescence resonance
energy transfer [9]. Elastase, proteinase 3 and CatG activities
at the surface of human neutrophils were determined with
fluorescence resonance energy transfer, and micellar electro-
kinetic chromatography (MEKC). MEKC was also use for
simultaneous determination of Pseudomonas aeruginosa
elastase, human leukocyte elastase and CatG activities [10].
In most cases activities of CatG are determined jointly by
modification of the Barrett’sm e t h o d[ 11], or using indirect
immunofluorescence and fixed granulocyte ELISA [12].
The aim of this work was to develop an SPRI biosensor
for the highly selective determination of CatG and to
demonstrate the sensor applicability for the determination
of the enzyme in different human body fluids. Highly
selective interaction of CatG with immobilized cathepsin
G inhibitor I (CGI-I) was utilised for sensor develop-
ment. CGI-I, a potent, selective, reversible, competitive,
non-peptide inhibitor of CatG (IC50 =5 3n m o l · L - 1a n d
Ki = 63 nmol·L-1) is a 620.6 Da-molecular compound.
CGI-I weakly inhibits chymotrypsin (Ki =1 . 5μmol·L-1)
and poorly inhibits thrombin, factor Xa, factor IXa,
plasmin, rypsin, tryptase, proteinase 3, and human leukocyte
elastase (IC50 > 100 μmol·L-1) [13]. The strategy for
designing the sensor involved the immobilization of thiol
(1-octadecanethiol) on a gold surface, and then the
immobilization of CGI-I using hydrophobic interactions.
The Surface Plasmon Resonance Imaging (SPRI) tech-
nique is a promising tool for the development of sensitive
sensors for biologically active species. It was applied for the
determination of β-2-microglobulin, mucin, novel protein
immunostimulating factor, microRNAs, DNA, cystatin C,
cysteine cathepsins, cathepsin D and E, papain [14–22].
Experimental
Reagents
CatG from human sputum, 1-octadecanethiol (ODM), Tween
20, (ALDRICH, Steinheim, Germany, www.sigmaaldrich.
com), cathepsin B (CatB) from human liver, CGI-I
(CALBIOCHEM, Merck group, Merck Sp. z.o.o., Warsaw,
Poland, www.merck-chemicals.pl) were used, as well as
absolute ethanol, acetic acid, sodium hydroxide, sodium
chloride, sodium carbonate, sodium phosphate, potassium
phosphate, sodium acetate, potassium chloride, magnesium
chloride (all POCh, Gliwice, Poland, www.poch.com.pl),
HBS-ES solution pH=7.4 (0.01 M HEPES, 0.15 mol·L-1
sodium chloride, 0.005% Tween 20, 3 mmol·L-1 EDTA),
acetic buffer pH=3.79–5.57, phosphate buffer pH=7.17–
8.04, carbonate buffer pH=8.50–9.86 (all BIOMED, Lublin,
Poland, www.biomed.lublin.pl), photopolymer ELPEMER
SD 2054, hydrophobic protective paint SD 2368 UV SG-DG
(PETERS, Kempen, Germany, www.peters.de)w e r eu s e da s
received. Aqueous solutions were prepared with milliQ
water (Simplicity®MILLIPORE). Whole citrated blood was
provided by the Haematology Clinic of the Medical
University in Bialystok, Poland and saliva samples by the
volunteers. All samples were provided after obtaining the
requisite consent of the Bioethical Commission.
Chip preparation
Gold chips were manufactured as described in a previous
paper [24]. The gold surface of the chip was covered with
photopolymer and hydrophobic paint as described in a
previous paper [23]. 9×12 free gold surfaces were obtained.
Using this chip, nine different solutions can be simulta-
neously measured without mixing the tested solutions.
Twelve single SPRI measurements can be performed from
one solution.
SPRI measurements
SPRI measurements for protein array were performed as
described in the previous papers [21–23]. A schematic
diagram of the apparatus is given in Fig. 1. The SPRI set-up
consists of HeNe laser (JDS Uniphase, Edmund Industrial
Optics, USA), two glass lenses L1 (f=3 mm) and L2 (f=
300 mm), two polarizers (P1 and P2), mirror, prism and a
CCD camera.
The chip consists of 9 detection areas, each containing
an array of 12 spots. Spots are separated with photopolymer
while detection areas are separated by hydrophobic paint.
The picture of the chip is shown in Fig. 2a, while the image
of the chip obtained by the CCD camera is shown in
Fig. 2b.
Briefly, the measurements were performed at a fixed
angle of incident light and reflectivity was simultaneously
measured across an entire chip surface. The contrast values
obtained for all pixels across a particular sample single spot
were integrated. Thus the SPRI signal was integrated over
the single spot area. Background correction was applied.
408 E. Gorodkiewicz et al.NIH Image J version 1.42 software was used to
evaluate the SPRI images in 2D form. The signal was
measured twice on the basis of registered images, after
immobilisation of CGI-I and then after interaction with
CatG. The SPRI signal, which is proportional to
coupled biomolecules, was obtained from subtraction
between the signal before and after interaction with a
biomolecule for each spot separately.
CGI-I immobilization
Chips were rinsed with ethanol and water and dried under a
stream of nitrogen. They were then immersed in 10 mL of
2.7 mmol·L-1 ODM ethanolic solutions for at least 24 h.
The chips were further rinsed with ethanol and water and
dried under a stream of nitrogen. CGI-I solution (3 μLo f
CGI-I solution for each array of 12 spots) was placed on the
thiol-modified surface and incubated at room temperature
for 24 h [23].
Preparation of the standard curve
The response of the analytical SPRI signal for CatG
concentration was measured within a concentration range
between 0.25 and 2.5 ng·mL-1. The chip surface was
c o v e r e db yam o n o l a y e ro fO D Ma n dal a y e ro f
immobilized CGI-I (4.0 μg·mL-1). Experiments were
performed at pH=8.0. The interaction time was 10 min.
Preparation of biological samples
White blood cells
2 mL of whole blood was centrifuged over 15 min at
1,000 × g. As a result, plasma was separated and white
blood cells were collected. The solution of white blood
cells was diluted two-fold with a buffer of pH=8.0 and
transferred onto the sensor surface for 10 min. The
volume of the sample applied on each detection area was
3 μL. The surface of the biosensor was then washed six
times with the HBS-ES buffer. The SPRI measurement
was performed. Concentration was evaluated using a
calibration curve.
Saliva
3 mL of saliva (in fasting state) was centrifuged over
15 min at 100 × g and a supernatant was separated.
Finally, the sample was filtered three times through a
paper filter of medium density. The prepared saliva was
diluted two-fold with a buffer of pH=8.0 and transferred
onto the sensor surface for 10 min. The volume of
sample applied on each detection area was 3 μL. The
surface of the biosensor was then washed six times with
t h eH B S - E Sb u f f e r .T h eS P R Im e a s u r e m e n tw a sp e r -
formed. Concentration was evaluated using a calibration
curve.
Fig. 1 Scheme of SPRI set-up
Fig. 2 a Picture of chip
(A-photopolymer, B-free gold
surface, C-hydrophobic paint),
b Image of chip obtained by
CCD camera
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Influence of CGI-I concentration on the analytical signal
of CatG
The purpose of this investigation was to find the best
conditions for CatG determination. The investigation was
performed within a CGI-I concentration range of 0.25 to
6.0 μg·mL-1 at constant CatG concentration (1.0 ng·mL-1).
A series of 9 CGI-I solutions of increasing concentration
were measured (0.25, 0.75, 1.50, 2.25, 3.00, 3.75, 4.50,
5,25 and 6.00 μg·mL-1). These solutions were transferred
onto different points of the surface of a chip, which had
been previously modified with ODM. CGI-I was immobi-
lised during this treatment. The chip was then treated with
the CatG solution (1.0 ng·mL-1) for 10 min, rinsed with
water and dried, and the SPRI measurement was performed.
The results are given in Fig. 3.
The obtained curve is a Langmuir isotherm type, with
the plateau of the signal for CGI-I concentration above
3.00 μg·mL-1. A concentration of CGI-I equal to
4.00 μg·mL-1 was selected as optimal for further
investigation.
Influence of solution pH on the interaction process
The influence of pH of CatG solution on the SPRI signal
was studied for 13 different pH values (within the range
3.0–10.0) under conditions of constant concentrations of
CatG (1 ng·mL-1) and CGI-I (4.0 μg·mL-1). Solutions of
CGI-I were transferred onto different points of a chip which
had been previously modified with ODM. In this manner
CGI-I was immobilised onto the chip surface. The chip was
then treated with CatG solutions (1 ng·mL-1) with different
pH values, for 10 min. The results are shown in Fig. 4.
As is apparent from the diagram, the maximum of the
SPRI signal for CGI-I—CatG complex is for pH=8.0. The
value of pH=8.0 was selected as optimal for further
investigation.
Analytical response of the sensor to CatG concentration.
Calibration curves
The response of the analytical SPRI signal for CatG
concentration was measured within a range of concen-
tration of between 0.25 and 2.5 ng·mL-1. The chip
surface was covered by a monolayer of ODM and a layer
of immobilized CGI-I (4.0 μg·mL-1). The experiments
were performed at pH=8.0. The time of interaction was
10 min. The obtained calibration curve is shown in
Fig. 5.
The calibration curves represent a Langmuir isotherm
type with the dynamic response range between 0.25 and
Fig. 3 Dependence of SPRI signal (Arbitrary Units) of CGI-I—CatG
complex on CGI-I concentration. CatG concentration: 1.0 ng·mL-1.
Initial pH of CatG solution: 8.0
Fig. 4 Dependence of SPRI signal (Arbitrary Units) of CGI-I—CatG
complex on pH. Initial CGI-I concentration: 4.0 μg·mL-1. Initial CatG
concentration: 1 ng·mL-1
Fig. 5 Dependence of SPRI signal (Arbitrary Units) on CatG
concentration. Initial pH value of CatG solution: 8.0
410 E. Gorodkiewicz et al.1.5 ng·mL-1 (0.01–0.06 nmol·L-1). This section is useful
for analytical purposes. The plateau of the curve
corresponds to saturation of active points of the sensor.
The detection limit calculated on the 3 S.D. basis is
e q u a lt o0 . 1 2n g · m L - 1 .
Selectivity of the CGI-I—CatG interaction
In order to be sure that the interaction between CGI-I
and CatG is selective and the sensor does not react with
the other enzymes of the cathepsin family, the chip
containing immobilised CGI-I was treated with mixtures
of CatG and CatB. Various excesses of CatB within the
range from 1:1 to 1:1000 were examined. Results are
s h o w ni nT a b l e1.
The results show no influence of CatB on the results
of determination of CatG even at a 1000-fold excess.
Thus sensor high selectivity was confirmed.
The problem of the development of a specific
sensor for CatG requires a specific inhibitor for this
cathepsin. There is only one commercially available
inhibitor of CatG, which was used in this research.
However, there are reports about developments of new
potent inhibitors of CatG [2]. Construction of a
biosensor with the use of one of them is the subsequent
goal of the authors.
Precision of the method for CatG determination
Precision of the method was tested under optimal con-
ditions, i.e. pH=8.0 and CGI-I concentration at the chip
preparation stage equal to 4.0 μg·mL-1. The precision of
CatG determination was tested for the concentration of this
enzyme equal to 1.00 ng·mL-1. The results are shown in
Table 2.
Standard deviation and the confidence limit, assuming
that the confidence level equals 95%, are relatively high.
This indicates that the biosensor has a relatively low
precision. However, the effect of relatively poor precision
is compensated by large number of repetitions, because the
sensor is an array of 12 analyzed spots. Therefore,
recoveries of spikes are good.
Recovery of the method was checked by addition of
spikes of CatG into a real samples of white blood cells. The
results are given in Table 3.
Atomic force microscopy measurements
Atomic Force Microscopy (AMF) enables observation of the
surface of the biosensor. AFM was used to confirm the
creation of each layer: thiol (ODM), inhibitor (CGI-I) and the
enzyme (CatG). Pictures were taken of bare gold (Fig. 6a),
ODM (Fig. 6b), CGI-I (Fig. 6c) and CatG (Fig. 6d). The
presented AFM pictures confirm that the described stages of
the creation of each layer on the biosensor surface have
really taken place. This may be concluded on the basis of the
creation of different structures after each stage.
CatG determination in real samples
White blood cells samples
Samples of white blood cells from 9 patients suffering
from leukemia were analysed for CatG determination
using the sensor. The results for patients are given in
Table 4. Concentration of CatG in white blood cells of
donors was below the detection limit, so it could not be
estimated.
Obtained results for CatG in white blood cells of patients
suffering from leukemia are within the range of 2.37 to
234.14 10
−5 ng·10
3 white blood cells. Due to different type
and stage of leukemia, these concentrations varied within a
wide range.
Saliva samples
CatG was determined in 6 samples of saliva in order to
demonstrate the sensor’s applicability to this purpose. The
results are shown in Table 5.
The range of CatG concentration in the saliva of donors
aged 19–24 is between 1.25 and 2.17 ng·mL-1, while
Table 1 Influence of CatB on results of CatG determination.
Concentration of CatG: 1 ng￿mL-1
CatG :
CatB
Added CatG
[ng￿mL-1]
Found CatG
[ng￿mL-1]
Recovery
[%]
1: 1 1.00 1.06±0.02 106
1: 10 1.00 1.10±0.11 110
1: 100 1.00 1.01±0.09 101
1: 1000 1.00 1.02±0.05 102
Table 2 Precision of concentration measurement of CatG
Number of measurements Added
[ng￿mL-1]
Found
[ng￿mL-1]
Recovery [%] S.D.
[ng￿mL-1]
Confidence (confidence limit,
95%) [ng￿mL-1]
CatG 24 1.00 1.02 102 0.39 0.15
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3.51 ng·mL-1. The changes of CatG activity in saliva can
play an important role in the pathobiochemistry and
diagnostics of salivary gland, gingiva, and oral mucosa
diseases. It is worth stressing that an elevated CatG
concentration in saliva can be a symptom of oral cavity
diseases [25].
Conclusions
A selective SPRI array biosensor for the determination of
CatG has been developed. The sensor works on the basis of a
highly selective reaction between immobilised CGI-I and
CatG in solution. Under optimised conditions, the sensor
exhibits selectivity to cathepsin G, and the precision and
accuracy is well suited to enzyme determination. The sensor
can be used for the determination of CatG in white blood
cells and saliva.
Fig. 6 AFM pictures of bare
gold (a), 1-octadecanethiol
(b), CGI-I (c) and CatG (d)
Table 4 Concentration of CatG in white blood cells of patients
suffering from leukemia
Patient number Type of leukaemia Mass of CatG in white
blood cells 10
5 [ng￿10
3
white blood cells]
1 AML 31.12±1.11
2 CLL 13.63±0.55
3 CML 2.37±0.11
4 CLL 21.02±2.18
5 BL 131.25±6.86
6 CLL 234.14±3.01
7 CLL 14.07±0.18
8 CLL 122.27±3.02
9 CLL 82.86±3.56
CLL chronic lymphocytic leukaemia; CML chronic myelogenous
leukaemia; AML acute myelogenous leukaemia; BL Burkitt lymphoma
Table 3 Recoveries of spike CatG in white blood cells in comparison
to the addition of standard
CatG concentration
without spike [ng￿mL-1]
Added CatG
[ng￿mL-1]
Found CatG
[ng￿mL-1]
Recovery
[%]
1 0.81±0.01 0.50 1.31±0.03 98.11
2 0.98±0.03 0.50 1.48±0.04 98.97
3 0.76±0.05 0.50 1.27±0.05 101.05
4 0.95±0.05 0.50 1.46±0.04 98.56
5 0.88±0.04 0.50 1.38±0.05 99.04
6 0.91±0.03 0.50 1.41±0.04 100.72
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